Heron Therapeutics reported $16.18M in Cost of Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Alnylam Pharmaceuticals ALNY:US $ 40.81M 5.18M
Amarin AMRN:US $ 35.81M 13.57M
Ani Pharmaceuticals ANIP:US $ 35.29M 1.02M
Anika Therapeutics ANIK:US $ 14.8M 0.09M
Eisai 4523:JP Y 47404M 3334M
Emergent Biosolutions EBS:US $ 169.8M 13.9M
Endo International Ordinary Shares ENDP:US $ 263.79M 84.03M
Esperion Therapeutics ESPR:US $ 9.18M 2.05M
GlaxoSmithKline GSK:LN 2136M 1509M
Heron Therapeutics HRTX:US $ 16.18M 4.82M
Insmed INSM:US $ 16.4M 4.2M
JAZZ PHA JAZZ:US $ 124.21M 8.92M
Ligand Pharmaceuticals LGND:US $ 12.36M 7.66M
Merk MRK:US $ 3698M 1636M
Nektar Therapeutics NKTR:US $ 5.12M 0.2M
Neurocrine Biosciences NBIX:US $ 4.8M 0.2M
Pacira Pharmaceuticals PCRX:US $ 50.63M 14.55M
Regeneron Pharmaceuticals REGN:US $ 297.1M 107.8M
Surmodics SRDX:US $ 5.14M 0.03M
Teva Pharmaceutical Industries TEVA:US $ 1958M 99M
Ultragenyx Pharmaceutical RARE:US $ 8.27M 2.17M
Veracyte VCYT:US $ 25.03M 1.32M
Vertex Pharmaceuticals VRTX:US $ 261.8M 16M